Information letter to health care professionals regarding the safe use of the medicinal product DUOSTAD. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

06.02.2026 Updated 11.02.2026 634 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарського засобу ДУОСТАД. Лікарські засоби, що містять фінастерид (finasteride) та дутастерид (dutasteride): нові заходи щодо мінімізації ризику суїцидальних думокPDF · 757 КБ

Завантажити

Information letter to health care professionals regarding the safe use of the medicinal product DUOSTAD. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the safe use of the medicinal product DUOSTAD. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration